Literature DB >> 24183066

Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.

Matthias Guckenberger1, Rainer Johannes Klement, Michael Allgäuer, Steffen Appold, Karin Dieckmann, Iris Ernst, Ute Ganswindt, Richard Holy, Ursula Nestle, Meinhard Nevinny-Stickel, Sabine Semrau, Florian Sterzing, Andrea Wittig, Nicolaus Andratschke, Michael Flentje.   

Abstract

BACKGROUND AND
PURPOSE: To compare the linear-quadratic (LQ) and the LQ-L formalism (linear cell survival curve beyond a threshold dose dT) for modeling local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: This study is based on 395 patients from 13 German and Austrian centers treated with SBRT for stage I NSCLC. The median number of SBRT fractions was 3 (range 1-8) and median single fraction dose was 12.5 Gy (2.9-33 Gy); dose was prescribed to the median 65% PTV encompassing isodose (60-100%). Assuming an α/β-value of 10 Gy, we modeled TCP as a sigmoid-shaped function of the biologically effective dose (BED). Models were compared using maximum likelihood ratio tests as well as Bayes factors (BFs).
RESULTS: There was strong evidence for a dose-response relationship in the total patient cohort (BFs>20), which was lacking in single-fraction SBRT (BFs<3). Using the PTV encompassing dose or maximum (isocentric) dose, our data indicated a LQ-L transition dose (dT) at 11 Gy (68% CI 8-14 Gy) or 22 Gy (14-42 Gy), respectively. However, the fit of the LQ-L models was not significantly better than a fit without the dT parameter (p=0.07, BF=2.1 and p=0.86, BF=0.8, respectively). Generally, isocentric doses resulted in much better dose-response relationships than PTV encompassing doses (BFs>20).
CONCLUSION: Our data suggest accurate modeling of local tumor control in fractionated SBRT for stage I NSCLC with the traditional LQ formalism.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biologically effective dose; Dose–response modeling; Linear-quadratic formalism; Non-small cell lung cancer; Stereotactic body radiotherapy

Mesh:

Year:  2013        PMID: 24183066     DOI: 10.1016/j.radonc.2013.09.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  25 in total

Review 1.  Radiation dose effect in locally advanced non-small cell lung cancer.

Authors:  Feng-Ming Spring Kong; Jing Zhao; Jingbo Wang; Corrine Faivre-Finn
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

3.  Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors.

Authors:  Abraham J Wu; Eric Williams; Ankit Modh; Amanda Foster; Ellen Yorke; Andreas Rimner; Andrew Jackson
Journal:  Radiother Oncol       Date:  2014-07-23       Impact factor: 6.280

Review 4.  ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams : Statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery.

Authors:  Lotte Wilke; Nicolaus Andratschke; Oliver Blanck; Thomas B Brunner; Stephanie E Combs; Anca-Ligia Grosu; Christos Moustakis; Daniela Schmitt; Wolfgang W Baus; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2019-01-16       Impact factor: 3.621

Review 5.  Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.

Authors:  Feng Liu; An Tai; Percy Lee; Tithi Biswas; George X Ding; Isaam El Naqa; Jimm Grimm; Andrew Jackson; Feng-Ming Spring Kong; Tamara LaCouture; Billy Loo; Moyed Miften; Timothy Solberg; X Allen Li
Journal:  Radiother Oncol       Date:  2016-11-18       Impact factor: 6.280

6.  Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.

Authors:  Jeho Jeong; Jung Hun Oh; Jan-Jakob Sonke; Jose Belderbos; Jeffrey D Bradley; Andrew N Fontanella; Shyam S Rao; Joseph O Deasy
Journal:  Clin Cancer Res       Date:  2017-05-24       Impact factor: 12.531

Review 7.  Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer.

Authors:  Susanne Temming; Martin Kocher; Erich Stoelben; Lars Hagmeyer; De-Hua Chang; Konrad Frank; Khosro Hekmat; Juergen Wolf; Wolfgang W Baus; Robert Semrau; Christian Baues; S Marnitz
Journal:  Strahlenther Onkol       Date:  2017-08-15       Impact factor: 3.621

8.  Technical Note: Break-even dose level for hypofractionated treatment schedules.

Authors:  Till Tobias Böhlen; Jean-François Germond; Jean Bourhis; Marie-Catherine Vozenin; Claude Bailat; François Bochud; Raphaël Moeckli
Journal:  Med Phys       Date:  2021-10-22       Impact factor: 4.506

9.  Evaluation of the cell survival curve under radiation exposure based on the kinetics of lesions in relation to dose-delivery time.

Authors:  Yusuke Matsuya; Kaori Tsutsumi; Kohei Sasaki; Hiroyuki Date
Journal:  J Radiat Res       Date:  2014-10-29       Impact factor: 2.724

10.  Revisiting the formalism of equivalent uniform dose based on the linear-quadratic and universal survival curve models in high-dose stereotactic body radiotherapy.

Authors:  Mark Ka Heng Chan; Chi-Leung Chiang
Journal:  Strahlenther Onkol       Date:  2020-11-27       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.